CYBN.NECybin Inc.
Oct 15, 2026 — Phase 2/3 Clinical Data Update
Chart by TradingViewThe schedule
- Thu15Oct
Key efficacy readout for CYB003/CYB004 psychedelic therapy programs.
- Thu10Dec
Management guidance on FDA interactions and late-stage trial designs.
- Mon15Feb
Full-year financial print evaluating cumulative operational drain against clinical milestones.
- Sat14Aug
Q2 2027 earnings print focusing on capital constraints and commercial readiness.
